SuperGen Nixes Phase III For Orathecin Combination Use In Pancreatic Cancer
This article was originally published in Pharmaceutical Approvals Monthly
SuperGen is pulling the plug on plans for a randomized Phase III trial of its Orathecin combination therapy in first-line pancreatic cancer after a Phase II study fell short of a pre-specified threshold for median survival
You may also be interested in...
MGI Pharma’s recently submitted oral mucositis therapy Saforis and newly approved myelodysplastic syndromes agent Dacogen top a "deep and maturing pipeline" projected to drive corporate sales to $1 bil. by 2010, according the company.
SuperGen may develop Orathecin as combo therapy following NDA withdrawal. Firm withdrew application in advance of anticipated negative action from FDA. SuperGen is moving ahead with a combination trial with gemcitabine
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011